Kurma closes new fund at €250m
Kurma Partners announced a first closing of its new Biofund IV at €140m targeted to raise €250m to finance 16-20 life science companies.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Genentech takes over Regor’s RGT-419B for US$850m upfront
/in News/by Thomas GabrielczykGenentech, the US subsidiary of Swiss pharmaceutical giant Roche AG, has strengthened the company’s breast cancer pipeline by pre-licensing the global commercialisation rights to Regor Therapeutics’ RGT-419B for US$850m.
Spima Therapeutics starts with global licence agreement
/in News/by Thomas GabrielczykSPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001
EFSA updates guidelines on cultured proteins and Novel Food
/in News/by Thomas GabrielczykThe EU’s food watchdog EFSA has updated its guidelines for novel food applications including cell-based and fermented foods to streamline approval times and clarify that food safety is its highest priority when recommending novel food products for market authorisation.
Long version of The BIOSECURE Act: The West’s Wake-Up Call to China’s Biotech Dominance
/in News/by Thomas GabrielczykBy Jeremy Levin, D.Phil, MB BChir
Asabys Partners close €180m Sabadell Asabys II Fund
/in News/by Thomas GabrielczykAsabys Partners have announced the closing of a new oversubscribed fund aimed at investing in 12-15 companies across all areas of pharma biotech.
Genespire raises US$52m in Series B round
/in News/by Thomas GabrielczykItalian SR-Tiget spin out Genespire srl will use the proceeds of a €46.6m (US$52m) Series B financing to advance its paediatric in-vivo gene therapy for the rare metabolic disorder Methylmalonic Acidemia (MMA) to Phase I/II testing.
AMR Accelerator urges long-term funding
/in News/by Thomas GabrielczykAntimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving nine European projects and 98 organisations is now calling for long-term investment to maintain Europe’s ability to research and develop new antibiotics.
Vicebio Ltd cashes in US$100m in Series B financing
/in News/by Thomas GabrielczykLondon-based Vicebio Ltd has announced a US$100m Series B financing that will support Phase I testing of its bivalent RSV vaccine candidate VXB-241 and pushing development of another pipeline programme.
French Brenus AS closes US$25m financing
/in News/by Thomas GabrielczykFrench Brenus Pharma SA has raised €22.2m (US$25m) to accelerate clinical trials of two precision cancer vaccines derived from tumour cell banks representing more than 200 tumour antigens.